

IFD

1637



ATTORNEY DOCKET NO. 21101.0047U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
Kevin M. Flanigan, <i>et al.</i>)	Art Unit: 1637
Application No. 10/539,178)	Examiner: Teresa E. Strzelecka
Filing Date: January 23, 2006)	Confirmation No. 2241
For: RAPID DIRECT SEQUENCE ANALYSIS OF MULTI-EXON GENES)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

May 3, 2007

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. §1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Copies of any cited foreign patent document and/or any non-patent publication are enclosed.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(3), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

ATTORNEY DOCKET NO. 21101.0047U2
Application No. 10/539,178

No fee is believed due; however, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.



Christopher L. Curfman, JD, PhD
Registration No. 52,787

NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.



Christopher L. Curfman, JD, PhD

May 3, 2007
Date



**ATTORNEY DOCKET NO. 21101.0047U2
APPLICATION NO. 10/539,178
SHEET 1 OF 1**

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/539,178
Filing Date	January 23, 2006
First Named Inventor	Flanigan, et al.
Group Art Unit	1637
Examiner Name	Teresa E. Strzelecka

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No
	C1	WO 96/16175	May 30, 1996	Association Française Contre Les Myopathies	
	C2	WO 00/11157	March 2, 2000	The General Hospital Corporation	

NON-PATENT DOCUMENTS

Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
	C3	Aoki <i>et al.</i> , "Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy," <i>Neurology</i> 57:271-278 (2001)
	C4	Aoki <i>et al.</i> , "Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy," <i>Neurology Supplementary Web Site</i> (2001)
	C5	Liu <i>et al.</i> , "Dyferlin, a novel skeletal muscle gene is mutated in Miyoshi myopathy and limb girdle muscular dystrophy," <i>Nature Genetics</i> 20:31-36 (1998)
	C6	Richard <i>et al.</i> , "Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A," <i>Cell</i> 81:27-40 (1995)
	C7	Ueyama <i>et al.</i> , "A new dysferlin gene mutation in two Japanese families with limb-girdle muscular dystrophy 2B and Miyoshi myopathy," <i>Neuromuscular Disorders</i> 11:139-145 (2001)
	C8	Supplemental Partial European Search Report for European Application No. 03799963.8, dated March 19, 2007

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.